Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Atea Pharmaceuticals

Atea Pharmaceuticals (NASDAQ: AVIR) insider transactions

In the twelve months to 10 November 2026, executives and directors of Atea Pharmaceuticals reported no open-market sales and no open-market purchases, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Atea Pharmaceuticals shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
18 June 2026Murphy Polly A.DirectorOption exercise+29,600—121,745Form 4
18 June 2026Polsky BruceDirectorOption exercise+29,600—124,806Form 4
18 June 2026Adams Jerome M.DirectorOption exercise+29,600—92,350Form 4
18 June 2026Duncan Barbara GayleDirectorOption exercise+29,600—92,350Form 4
18 June 2026Berger Franklin MDirectorOption exercise+29,600—536,097Form 4
18 June 2026Lucidi BrunoDirectorOption exercise+29,600—142,350Form 4
11 March 2026Corcoran AndreaSee RemarksOption exercise+60,000$1.24823,576Form 4
3 February 2026Sommadossi Jean-PierrePresident, CEO, and ChairmanOption exercise+300,000$1.24767,830Form 4
31 January 2026Foster WayneEVP, Chief Accounting OfficerOption exercise+41,333—91,461Form 4
31 January 2026Foster WayneEVP, Chief Accounting OfficerShares withheld for tax−12,132$4.2479,329Form 4
31 January 2026Sommadossi Jean-PierrePresident, CEO, and ChairmanOption exercise+272,983—573,923Form 4
31 January 2026Sommadossi Jean-PierrePresident, CEO, and ChairmanShares withheld for tax−106,093$4.24467,830Form 4
31 January 2026Corcoran AndreaSee RemarksOption exercise+54,866—779,680Form 4
31 January 2026Corcoran AndreaSee RemarksShares withheld for tax−16,104$4.24763,576Form 4
31 January 2026Hammond Janet MJChief Development OfficerOption exercise+58,050—141,801Form 4
31 January 2026Hammond Janet MJChief Development OfficerShares withheld for tax−14,136$4.24127,665Form 4
31 January 2026Vavricka JohnChief Commercial OfficerOption exercise+42,083—94,164Form 4
31 January 2026Vavricka JohnChief Commercial OfficerShares withheld for tax−11,570$4.2482,594Form 4
31 January 2026Horga Maria ArantxaChief Medical OfficerOption exercise+51,283—112,159Form 4
31 January 2026Horga Maria ArantxaChief Medical OfficerShares withheld for tax−16,073$4.2496,086Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Atea Pharmaceuticals page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.